[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-tumour\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-tumour":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100592634","early-phase-1-dosimetry-and-preliminary-clinical-application-study-of-a-novel-probe-targeting-cd73-100592634",false,"NCT06995976","Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73","Inclusion Criteria:\n\nSigned informed consent and be able to follow up.\n\nExclusion Criteria:\n\nPregnant or lactational women; who suffered from severe hepatic and renal insufficiency.",true,"ALL","18 Years","90 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.",[27],"Malignant Tumour","RECRUITING","2025-05-21",{"date":31,"type":32},"2025-05-30","ACTUAL",{"date":34,"type":32},"2025-03-01",{"date":36,"type":21},"2026-03-01",{"name":38,"class":39},"First Affiliated Hospital of Fujian Medical University","OTHER"]